Epidemiology of Prostate Cancer in the Republic of Kazakhstan

  • Dariga SMAILOVA Department of Innovations in Science, Semey Medical University, Semey, Republic of Kazakhstan
  • Erlan OSPANOV Department of Neurology, Ophthalmology, and ENT, Semey Medical University, Semey, Republic of Kazakhstan
  • Meruert GAZALIYEVA Department of Clinical Immunology, Allergology, and Microbiology, Karaganda Medical University, Karaganda, Republic of Ka-zakhstan
  • Dilyara KAIDAROVA Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan
  • Oxana SHATKOVSKAYA Kazakh Institute of Oncology and Radiology, Almaty, Republic of Kazakhstan
  • Zhanar ZAMANBEKOVA Department of Endocrinology, Semey Medical University, Semey, Republic of Kazakhstan
  • Kuralay AMRENOVA Department of Personalized Medicine, Semey Medical University, Semey, Republic of Kazakhstan
  • Tatyana BELIKHINA Semey Regional Oncology Center, Semey, Republic of Kazakhstan
  • Tasbolat ADYLKHANOV Department of Oncology, Semey Medical University, Semey, Republic of Kazakhstan
  • Ardak OMARBEKOV Department of Surgical Diseases №2, Astana Medical University, Astana, Republic of Kazakhstan
  • Marzhan DAULETYAROVA Research Office, Astana Medical University, Astana, Republic of Kazakhstan
  • Lyudmila PIVINA Department of Emergency Medicine, Semey Medical University, Semey, Republic of Kazakhstan
  • Yuliya SEMENOVA Mail Department of Neurology, Ophthalmology, and ENT, Semey Medical University, Semey, Republic of Kazakhstan
Prostate cancer, Morbidity, Mortality, Screening program, Kazakhstan


Background: The incidence and mortality from prostate cancer in most native Asian populations remain low although a gradual increase is observed over the last years.

Methods: The statistical analysis of official data on prostate cancer mortality and morbidity was performed for the whole country and for Pavlodar Region.

Results: The increase in the incidence of prostate cancer among the population of Kazakhstan is observed, which may be attributed to the introduction of screening program based on serum PSA. Still, the crude incidence rates in Kazakhstan are below world indices. Over the last few years, the decreasing prostate cancer mortality is observed that might be influenced by early diagnosis. The age-standardized incidence rates show that the majority of prostate cancer cases occur in advanced ages (70 years and older).

Conclusion: More research is needed to determine the risk factors for prostate cancer, as well as ethnic and geographical trends for the population of Kazakhstan.


1. WHO (2014). World cancer report. Geneva, 632 pages.
2. Dauletyarova M, Semenova Y, Kaylubaeva G et al (2016). Are Women of East Kazakhstan Satisfied with the Quality of Maternity Care? Implementing the WHO Tool to Assess the Quality of Hospital Services. Iran J Public Health, 45(6): 729-38.
3. Dauletyarova MA, Semenova YM, Kaylubaeva G et al (2018). Are Kazakhstani Women Satisfied with Antenatal Care? Implementing the WHO Tool to Assess the Quality of Antenatal Services. Int J Environ Res Public Health, 15:E325.
4. Ferlay J, Bray F, Pisani P, Parkin DM (2001). GLOBOCAN 2000: Cancer Incidence, Mor-tality and Prevalence Worldwide. IARC Cancer Base No. 5, Lyon: IARC.
5. Bray F, Ren JS, Masuyer E, Ferlay J (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer, 132: 1133–1145.
6. Forman D, Bray F, Brewster DH et al (2014). Cancer Incidence in Five Conti-nents, Vol. X [electronic version]. Lyon: IARC. Available from: http://ci5.iarc.fr
7. Giovannucci E, Platz EA, Mucci L (2011). Epidemiology of prostate cancer. In: Comprehensive Textbook of Genitourinary On-cology. Eds, Scardino, Linehan, Zelefsky et al. 4th ed, Lippincott Williams & Wilkins. Baltimore, pp. 1–17.
8. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C (2004). Leveling of prostate cancer mortality in Western Europe. Pros-tate, 60(1): 46-52.
9. Henderson BE, Lee NH, Seewaldt V, Shen H (2012). The influence of race and eth-nicity on the biology of cancer. Nat Rev Cancer, 12: 648–653.
10. Ospanov Е, Adylkhanov Т, Tokanova Sh et al (2017). Mortality and morbidity from prostate cancer in the Republic of Ka-zakhstan from 2007 to 2016. Georgian Med News, 272: 17-22.
11. Ishkinin YI, Zhylkaidarova A, Nurgaliyev N et al (2017). Population-based Prostate Cancer Screening in Kazakhstan. Iran J Public Health, 46(7): 917-922.
12. PDQ Screening and Prevention Editorial Board (2017). Prostate Cancer Screening. National Cancer Institute, Bethesda (USA). Available from: https://www.ncbi.nlm.nih.gov/books/NBK65945/
13. Moyer VA, U.S (2012). Preventive Services Task Force: Screening for prostate can-cer: US Preventive Services Task Force recommendation statement. Ann Intern Med, 157 (2): 120-34.
14. Djulbegovic M, Beyth RJ, Neuberger MM et al (2010). Screening for prostate cancer: systematic review and meta-analysis of randomized controlled trials. BMJ, 341: c4543.
15. Ilic D, O’Connor D, Green S, Wilt T (2007). Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control, 18: 279-285.
16. Yelissinova N, Grjibovski AM, Yelissinova A et al (2015). Sociodemographic factors associated with infant abandonment in maternity hospitals in Kazakhstan: A case-control study. Public health, 129(7): 1010-1013.
17. Dyussenova L, Pivina L, Semenova Y et al (2018). Associations between depression, anxiety and medication adherence among patients with arterial hypertension: com-parison between persons exposed and non-exposed to radiation from the Se-mipalatinsk Nuclear Test Site. J Environ Radioact, 195: 33–39.
18. Markabayeva A, Bauer S, Pivina et al (2018). Increased prevalence of essential hyper-tension in areas previously exposed to fallout due to nuclear weapons testing at the Semipalatinsk test site, Kazakhstan. Environ Res, 167: 129–135.
19. Shalgumbayeva GM, Rakhypbekov TK, Sagidullina GG et al (2014). Incidence of and mortality from cervical cancer in the territory adjacent to the former Semipalatinsk nuclear test site in 2008-2012. Ekologiia Cheloveka, 5(1): 41-47.
20. Schwerin M, Schonfeld S, Drozdovitch V et al (2010). The utility of focus group inter-views to capture dietary consumption da-ta in the distant past: dairy consumption in Kazakhstan villages 50 years ago. J Dev Orig Health Dis, 1(3): 192-202.
21. Parkin DM, Ferlay J, Curado MP et al (2010). Fifty years of cancer incidence: CI5 I-IX. Int J Cancer, 127: 2918–2927.
22. Ito K (2014). Prostate cancer in Asian men. Nat Rev Urol, 11(4): 197-212.
23. Ferlay J, Shin HR, Bray F et al (2010). Esti-mates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127: 2893–2917.
24. Center MM, Jemal A, Lortet-Tieulent J et al (2012). International variation in prostate cancer incidence and mortality rates. Eu-rUrol, 61: 1079–1092.
25. Merabishvili VM, Petrova NG, Atroshchenko AV, Kharitonov MV (2014). [Epidemiology of prostate cancer (cohort study)].Vopr Onkol, 60(4): 457-63.
26. Zalutskiĭ IV, Zhavrid EA, Mashevskiĭ AA et al (2009). [Oncological service in the Re-public of Belarus in 2008 and prospects for developmen]t. Vopr Onkol, 55(5): 555-61.
27. Merabishvili VM (2017). [Age-related risks of cancer (analytical indicators of registration and early diagnosis)]. Adv Gerontol, 30(6): 818-825.
28. Davydov MI, Aksel' EM (2007). The inci-dence of malignant tumors and mortality caused by them in Commonwealth of Independent States in 2005. Vestn Ross Akad Med Nauk, 11: 45-9.
29. Welton M, Robb SW, Shen Y, Guillebeau P, Vena J (2015). Prostate cancer incidence and agriculture practices in Georgia, 2000-2010. Int J Occup Environ Health, 21(3): 251-7.
30. Golovachev SV, Nurgaliev NS, Kamarli ZP, Makimbetov EK (2016). Status of oncological care and epidemiology of prostate cancer in the republics of Central Asia. Cancer Urology, 12(3): 82-86. [Article in Russian]
How to Cite
Original Article(s)